| Politician | Action | Description | Traded |
|---|---|---|---|
| Buy | INCYTE CORPORATION CMN | Sep 4, 2026 | |
| Buy | INCYTE CORP | Apr 30, 2026 | |
| Buy | INCYTE CORP | Apr 30, 2026 | |
| Buy | INCYTE CORP. CMN | Feb 17, 2026 | |
| Sell | INCYTE MARS OCEAN BIORESEARC | Feb 6, 2026 | |
| Sell | INCYTE CORP CMN | Feb 5, 2026 | |
| Sell | INCYTE CORPORATION CMN | May 19, 2025 | |
| Sell | Incyte Corporation | May 15, 2025 | |
| Buy | INCYTE CORP CMN | Feb 5, 2025 | |
| Sell | INCYTE CORPORATION CMN | Jan 17, 2025 |
This page tracks congressional stock trading activity in Incyte Corporation (INCY) in the Healthcare sector. Disclosed Capitol has indexed 53 disclosed congressional trades involving INCY. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.
As of October 2026 — Disclosed Capitol has tracked 53 disclosed congressional trades in Incyte Corporation (INCY) — 29:20 sell-heavy ratio — led by Ro Khanna (D).
| Date | Politician | Party | Action | Amount |
|---|---|---|---|---|
| Sep 4, 2026 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| Apr 30, 2026 | Michael McCaul | R | Buy | $50,001 - $100,000 |
| Apr 30, 2026 | Michael McCaul | R | Buy | $1,001 - $15,000 |
| Feb 17, 2026 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| Feb 6, 2026 | Michael McCaul | R | Sell | Over $50,000,000 |
| Feb 5, 2026 | Ro Khanna | D | Sell | $1,001 - $15,000 |
| May 19, 2025 | Ro Khanna | D | Sell | $1,001 - $15,000 |
| May 15, 2025 | Rob Bresnahan | R | Sell | $1,001 - $15,000 |
| Feb 5, 2025 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| Jan 17, 2025 | Ro Khanna | D | Sell | $1,001 - $15,000 |
Across the 53 disclosed congressional trades in Incyte Corporation (INCY), members of Congress have reported 20 buys and 29 sells. The average 30-day alpha vs. the S&P 500 is -0.98%.
As of September 2026, corporate insiders at Incyte Corporation have filed 1 SEC Form 4 transaction in INCY over the past 12 months.
| Date | Insider | Action | Value |
|---|---|---|---|
| 2026-09-30 | BAKER JULIAN — Director | Award | — |
Insider transactions are parsed from SEC Form 4 filings and shown alongside the congressional trades above. Institutional 13F positions are tracked separately on the institutional holdings page.
As of June 2026, Incyte Corporation has 35 federal contract award records on file from USAspending.gov — most recently $129K from the Department of Veterans Affairs on 2026-06-08.
| Award date | Agency | Amount |
|---|---|---|
| 2026-06-08 | Department of Veterans Affairs | $129K |
| 2026-03-27 | Department of Veterans Affairs | $500K |
| 2025-04-28 | Department of Veterans Affairs | $541K |
| 2024-09-20 | Department of Veterans Affairs | -$73K |
| 2024-07-02 | Department of Veterans Affairs | $120K |
| 2024-04-15 | Department of Veterans Affairs | $541K |
| 2024-02-28 | Department of Veterans Affairs | -$65K |
| 2023-10-05 | Department of Veterans Affairs | -$51K |
| 2023-04-11 | Department of Veterans Affairs | $675K |
| 2023-01-30 | Department of Veterans Affairs | $250K |
Negative amounts are contract de-obligations. Browse and filter every award on the government contracts page.
For fiscal year 2025, Incyte Corporation reported revenue of $5.14B and net income of $1.29B, per SEC filings.
Most recent reported quarter: Q1 FY2026 — revenue $1.27B, net income $303.3M.
Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.